NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN REAL CLINICAL PRACTICE: PROLONGED FOLLOW UP AND PROGNOSTIC FACTORS ANALYSIS

EHA Library, Lepik Kirill, 293621

THE COMBINED PROGNOSTIC ROLE OF INTERIM 18FDG-PET AND TARC IN HODGKIN LYMPHOMA

EHA Library, Laszlo Pinczes, 293622

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 4-YEAR UPDATE OF THE ECHELON-1 STUDY

EHA Library, Marco Picardi, 293624

EA(50)COPP-14 ± RADIOTHERAPY IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH ADVANCED STAGES OF CLASSICAL HODGKIN LYMPHOMA: RESULTS OF THE MODIFIED PROTOCOL «HLMOSCOW 1-3»

EHA Library, Gayane Tumyan, 293626

CARDIOVASCULAR DISEASES IN HODGKIN'S LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293627

OBJECTIVE RESPONSE RATES AND QUALITY OF LIFE CHANGES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL) RECEIVING BRENTUXIMAB VEDOTIN AS >2 LINE OF TREATMENT IN THE REAL WORLD SETTING

EHA Library, Tatyana Ionova, 293628

PARANEOPLASTIC CEREBELLAR DEGENERATION ASSOCIATED WITH HODGKIN LYMPHOMA : A FRENCH RETROSPECTIVE COHORT

EHA Library, Kentin Queru, 293629

PROGNOSTIC VALUE OF THE FUNCTIONAL PARAMETERS: TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TOTAL LESION GLYCOLYSIS (TLG) AT BASELINE [18F]FDG-PET/CT IN HODGKIN LYMPHOMA

EHA Library, Francisca Hernandez Mohedo, 293630

AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY TO DESCRIBE TREATMENT PATHWAYS AND OUTCOMES FOR CLASSICAL HODGKIN LYMPHOMA IN EAST ASIA: INTERIM RESULTS

EHA Library, Tae Min Kim, 293631

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND CLINICAL OUTCOMES IN THE FRONTLINE TREATMENT OF ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA IN ITALY, SPAIN, AND ISRAEL

EHA Library, Abraham Avigdor, 293632

CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN CHILDREN AND YOUNG-ADULTS WITH HODGKIN'S LYMPHOMA: A KPHOG LYMPHOMA WORKING-PARTY, MULTICENTER, RETROSPECTIVE STUDY

EHA Library, Jae Min Lee, 293633

IMPACT OF NIVOLUMAB ON OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Philippe Armand, 293634

REAL-LIFE VALIDATION OF A SIMPLIFIED INTERNATIONAL PROGNOSTIC SCORE VERSION (IPS-3) IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA

EHA Library, Theodoros P. Vassilakopoulos, 293635

SECONDARY MALIGNANCIES IN HODGKIN LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293636

TREATMENT PATHWAYS AND CLINICAL OUTCOMES OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN LATIN AMERICA: INTERIM RESULTS FROM AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY

EHA Library, Amado Karduss Urueta, 293637

THE HODGKIN LYMPHOMA INTERNATIONAL STUDY FOR INDIVIDUAL CARE (HOLISTIC): A MULTI-NATIONAL COLLABORATIVE TO ENHANCE DECISION MAKING FOR PEDIATRIC AND ADULT HODGKIN LYMPHOMA (HL)

EHA Library, Andrew Evens, 293638

THE EFFECTS OF THYROID DYSFUNCTION ON BONE REMODELING IN PATIENTS WITH HODGKIN'S LYMPHOMA

EHA Library, Mariia Voytko, 293639

TREATMENT PATTERNS AND EFFECTIVENESS OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA WHO RECEIVED AUTOLOGOUS AND/OR ALLOGENIC STEM CELL TRANSPLANTATION

EHA Library, Monika Raut, 293640

BRENTUXIMAB VEDOTIN CONSOLIDATION THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK HODGKIN'S LYMPHOMA: MULTI-CENTER REAL-LIFE EXPERIENCE

EHA Library, Burhan Ferhanoglu, 293641

FINAL ANALYSIS OF AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA.

EHA Library, DAVID SIBON, 293642

PROGNOSTIC ROLE OF END OF TREATMENT PET/CT DEAUVILLE SCORE IN HODGKIN LYMPHOMA.

EHA Library, Maria Lucia De Luca, 293643

BRENTUXIMAB VEDOTIN THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ALLOGENEIC STEM CELLS TRANSPLANTATION: SINGLE CENTER EXPERIENCE

EHA Library, Anastasiya Beynarovich, 293644

COMPARATIVE ANALYSIS OF THE VARIOUS THERAPEUTIC STRATEGIES USED IN HODGKIN'S LYMPHOMA WITH A MASSIVE MEDIASTINAL BULKY: BEACOPP VS ABVD AND RADIOTHERAPY TYPE COMPLETE MANTLE VERSUS IFRT

EHA Library, Talbi Faiza, 293645

THERAPEUTIC CHALLENGES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA – A SINGLE INSTITUTION LONG-STANDING EXPERIENCE

EHA Library, Krasen Venkov, 293646

FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE GALLIUM STUDY: PROGNOSTIC VALUE OF PET-CT STATUS AFTER LONG-TERM FOLLOW-UP

EHA Library, Judith Trotman, 293647

CONDITIONAL RELATIVE SURVIVAL AMONG PATIENTS WITH FOLLICULAR LYMPHOMA IN THE NETHERLANDS: A POPULATION-BASED STUDY, 1989-2017

EHA Library, Manette Dinnessen, 293648

FOCUS ON PATIENTS WITH TP53 DISRUPTION IN THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL: UNIFORM POOR OUTCOME, REGARDLESS OF BASELINE PREDICTORS, MRD STATUS AND LENALIDOMIDE MAINTENANCE

EHA Library, Simone Ferrero, 293649

MAGNIFY: PHASE IIIB INTERIM ANALYSIS OF INDUCTION LENALIDOMIDE + RITUXIMAB (R2) FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

EHA Library, Mathias Rummel, 293650

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + VENETOCLAX (VEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

EHA Library, Sam Yuen, 293651

CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA PATIENTS WITH HIGH RISK BIOLOGY (HIGH KI-67, BLASTIC MCL, OR HIGH P53 EXPRESSION)

EHA Library, Martin Dreyling, 293652

IINVOLVED FIELD RADIATION THERAPY (IFRT) ± LOW-DOSE TOTAL BODY IRRADIATION (TBI) FOR LOCALIZED INDOLENT B-NHL: FINAL ANALYSIS OF RANDOMIZED EORTC TRIAL 20971-22997

EHA Library, Igor Aurer, 293653

PHASE 1/2 STUDY OF SINGLE-AGENT ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Alessandra Tedeschi, 293654

CONCURRENT TP53 AND CDKN2A GENE ABERRATIONS IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA CORRELATE WITH CHEMORESISTANCE AND CALL FOR INNOVATIVE UPFRONT THERAPY

EHA Library, Diana Malarikova, 293655

TREATMENT AND SURVIVAL IN PRIMARY CUTANEOUS MARGINAL ZONE LYMPHOMA: A POPULATION-BASED STUDY

EHA Library, Lei Fan, 293656

THREE-YEAR FOLLOW-UP OF TREATMENT-NAÏVE AND PREVIOUSLY TREATED PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) RECEIVING SINGLE AGENT ZANUBRUTINIB

EHA Library, Stephen Opat, 293657

OUTCOMES OF RELAPSED/REFRACTORY MCL PATIENTS TREATED WITH ZANUBRUTINIB MONOTHERAPY IN THE SECOND LINE AND IN LATER LINES: A POOLED ANALYSIS FROM 2 STUDIES

EHA Library, Keshu Zhou, 293658

SUSTAINED CLINICAL BENEFIT OF OBINUTUZUMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: UPDATED RESULTS FROM THE GALLIUM STUDY

EHA Library, William Townsend, 293659

FEASIBILITY OF COMBINING THE PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITOR COPANLISIB WITH RITUXIMAB (R)-BASED IMMUNOCHEMOTHERAPY IN PATIENTS (PTS) WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (INHL)

EHA Library, Pier Luigi Zinzani, 293660

INTERIM RESULTS OF R-BAC/R-C FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MANTLE CELL LYMPHOMA WITHOUT TP53 MUTATION

EHA Library, Daria Koroleva, 293661

SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX INPREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.

EHA Library, Anastasios Stathis, 293662

THE PI3KΔ INHIBITOR ME-401 IS WELL-TOLERATED ON INTERMITTENT SCHEDULE AND PRODUCES A HIGH-RATE OF DURABLE RESPONSES IN RELAPSED/REFRACTORY (R/R) INDOLENT B-CELL MALIGNANCIES

EHA Library, JM Pagel, 293663

PATIENTS WITH GRADE 3B FOLLICULAR LYMPHOMA EXPERIENCE SUPERIOR OUTCOMES COMPARED WITH DIFFUSE LARGE CELL LYMPHOMA, BUT SHOW A CONTINUOUS PATTERN OF RELAPSE

EHA Library, Allison Barraclough, 293664

CORRELATION OF THE MCL35 SCORE AND GENE MUTATIONS WITH OUTCOME IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN THE MCL3001 RAY TRIAL

EHA Library, Ciara L Freeman, 293665

IBRUTINIB AS SECOND-LINE THERAPY IS WELL TOLERATED AND EFFICACIOUS IN FRAIL PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA WHO ARE UNSUITABLE FOR STANDARD FRONT-LINE THERAPIES

EHA Library, Sophie Johns, 293666

CLARITHROMYCIN AND LENALIDOMIDE COMBINATION: A FULL ORAL REGIMEN FOR RELAPSED/REFRACTORY MALT LYMPHOMA PATIENTS. RESULTS OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG40/CLEO TRIAL

EHA Library, Andrés Ferreri, 293667

END-OF-TREATMENT 18[F]-FDG PET CAN PREDICT PROGRESSION-FREE SURVIVAL IN PATIENTS UNDERGOING BENDAMUSTINE-RITUXIMAB FOR FIRST RELAPSED/RECURRENT FOLLICULAR LYMPHOMA: A PROSPECTIVE W-JHS NHL01 TRIAL

EHA Library, Shinya Rai, 293668

UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH MYD88 WILD-TYPE WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Meletios Dimopoulos, 293669

THE INTERVAL BETWEEN FRONTLINE TREATMENT AND SECOND RELAPSE (PFS2) PREDICTS SURVIVAL FROM SECOND RELAPSE (SFR2) IN FOLLICULAR LYMPHOMA PATIENTS

EHA Library, Pablo Mozas, 293670

CAN 18F-FDG PET/CT OVERCOME ENDOSCOPY IN THE STAGING OF GASTROINTESTINAL INVOLVEMENT IN MANTLE CELL LYMPHOMA? A RETROSPECTIVE MULTI-CENTER COHORT ANALYSIS.

EHA Library, Tetiana Skrypets, 293671

OUTCOMES BASED ON INDICATION FOR TREATMENT AND CHOICE OF FRONTLINE REGIMEN IN WALDENSTRÖM'S MACROGLOBULINAEMIA

EHA Library, Oliver Tomkins, 293672

CLINICAL MOLECULAR DIAGNOSTICS LABORATORY VALIDATION OF THE MCL35 GENE EXPRESSION PROFILING ASSAY FOR MOLECULAR RISK STRATIFICATION OF MANTLE CELL LYMPHOMA

EHA Library, Ryan S. Robetorye, 293673

IDELALISIB IMMUNE-RELATED TOXICITY PREDICTS IMPROVED TREATMENT RESPONSE FOR INDOLENT NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Nina Wagner-Johnston, 293674

A LOW LYMPHOCYTE TO MONOCYTE RATIO (LMR) IS AN INDEPENDENT PREDICTOR OF POORER SURVIVAL AND HIGHER RISK OF HISTOLOGICAL TRANSFORMATION IN PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Pablo Mozas, 293675

CLINICAL CHARACTERISTICS AND OUTCOMES OF PRIMARY VERSUS SECONDARY GASTROINTESTINAL MANTLE CELL LYMPHOMA

EHA Library, Aung Tun, 293676

LRPAP1-AUTOANTIBODIES IN MANTLE CELL LYMPHOMA APPEAR TO BE ASSOCIATED WITH AN IMPROVED OUTCOME

EHA Library, Lorenz Thurner, 293677

ALTERNATIVE ANTI-CD20 ANTIBODY VERSUS DESENSITIZATION FOR LYMPHOMA PATIENTS WITH DRUG HYPERSENSITIVITY REACTIONS REQUIRING DISCONTINUATION OF RITUXIMAB, OBINUTUZUMAB OR OFATUMUMAB.

EHA Library, Paola Ghione, 293678

TREATMENT PRACTICES AND PATIENT BURDEN IN MANTLE CELL LYMPHOMA PATIENTS IN THE REAL WORLD: AN OBSERVATIONAL, DATABASE RESEARCH IN JAPAN (CLIMBER-DBR)

EHA Library, Hirokazu Nagai, 293679

PREDICTING OUTCOMES IN FOLLICULAR LYMPHOMA – HOW BETTER IS PRIMA-PI?

EHA Library, Carolina Afonso, 293680

A PREDICTIVE MODEL FOR T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKAEMIA: A SINGLE-CENTER EXPERIENCE OF 119 PATIENTS

EHA Library, Lei Fan, 293681

OUTCOME OF WATCHFUL WAITING IN PATIENTS WITH FOLLICULAR LYMPHOMA AT THE FIRST RELAPSE

EHA Library, Takahiro Fujino, 293683

BENDAMUSTINE PLUS RITUXIMAB IN WALDENSTRÖM MACROGLOBULINAEMIA: DEEPER RESPONSES, LONGER SURVIVAL AND LESS TOXICITY IN THE FRONTLINE SETTING

EHA Library, Suzanne Arulogun, 293684

RESPONSE-ADAPTED APPROACH IN MANTLE CELL LYMPHOMA (CT/PET AND MRD ASSESSMENT) ENABLES CR PATIENTS TO AVOID ASCT FOLLOWING INTENSIVE CHEMO-IMMUNOTHERAPY

EHA Library, Jocelyn Tan, 293685

MANAGING TOXICITIES OF PI3K INHIBITORS: IMPACT OF ALIGNED INTERPROFESSIONAL CLINICIAN AND PATIENT EDUCATION

EHA Library, Lauren Willis, 293686

PROGNOSTIC FATORS AND VALIDATION OF THE MALT-IPI IN NON-GASTRIC MALT LYMPHOMAS: REAL LIFE EXPERIENCE IN A SERIES OF 198 PATIENTS.

EHA Library, Christina Kalpadakis, 293687

SAFETY PROFILE OF RITUXIMAB BIOSIMILAR CT-P10 IN FOLLICULAR LYMPHOMA: A POOLED ANALYSIS OF FINAL DATA FROM CT-P10 PHASE 3 FOLLICULAR LYMPHOMA STUDIES

EHA Library, Christian Buske, 293688

IBRORS-MCL STUDY: CLINICAL OUTCOMES OF A SPANISH RETROSPECTIVE AND OBSERVATIONAL STUDY OF RELAPSED/REFRACTORY MANTLE-CELL LYMPHOMA (MCL) TREATED WITH IBRUTINIB IN ROUTINE CLINICAL PRACTICE

EHA Library, Juan Manuel Sancho, 293689

CD20-TCB IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA: DURABLE COMPLETE RESPONSES AND MANAGEABLE SAFETY OBSERVED AT CLINICALLY RELEVANT DOSES IN PHASE I DOSE ESCALATION

EHA Library, Michael J Dickinson, 293690

LONG-TERM OUTCOMES FROM THE PHASE II L-MIND STUDY OF TAFASITAMAB (MOR208) PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Gilles Salles, 293691

AN IMMUNE-RELATED PROGNOSTIC CLASSIFIER ASSOCIATED WITH DIFFUSELARGE B-CELL LYMPHOMA MICROENVIRONMENT

EHA Library, Liang Wang, 293692

CLINICOPATHOLOGICAL CHARACTERISTICS AND MYC STATUS DETERMINE TREATMENT OUTCOME IN PLASMABLASTIC LYMPHOMA: A MULTI-CENTER STUDY OF 76 CONSECUTIVE PATIENTS

EHA Library, Hanno M Witte, 293693

PROOF OF CONCEPT FOR TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL): PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE 2 STUDY

EHA Library, Dr. Thomas Witzig, 293694

EARLY RESPONSE OBSERVATION IN ALK KINASE INHIBITORS COMBINED WITH/WITHOUT VINBLASTINE IN PEDIATRIC REFRACTORY/RELAPSED ALK+ ANAPLASTIC LARGE CELL LYMPHOMA

EHA Library, Yonghong Zhang, 293695

OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED WITH HEPATITIS C VIRUS IN ELDERLY PATIENTS: RESULTS OF THE PROSPECTIVE 'ELDERLY PROJECT' BY THE FONDAZIONE ITALIANA LINFOMI (FIL)

EHA Library, Annalisa Arcari, 293696

FDG PET DELTA SUVMAX FOLLOWING 4 CYCLES RATHER THAN 2 CYCLES OF R-CHOP PREDICTS STRONGLY FOR REFRACTORY DISEASE IN AGGRESSIVE B CELL NON-HODGKIN LYMPHOMA

EHA Library, Joel Wight, 293697

NO SEX-RELATED DIFFERENCE IN RELATIVE SURVIVAL AMONG ELDERLY PATIENTS WITH DLBCL TREATED WITH R-CHOP: A CONTEMPORARY, NATIONWIDE, POPULATION-BASED STUDY IN THE NETHERLANDS

EHA Library, Mujde Durmaz, 293698

EXPLORATION OF TUMOR BIOPSY GENE SIGNATURES TO UNDERSTAND THE ROLE OF THE TUMOR MICROENVIRONMENT IN OUTCOMES TO LISOCABTAGENE MARALEUCEL (LISO-CEL)

EHA Library, N. Eric Olson, 293699

REAL-WORLD RESULTS OF ANTI-CD19 CAR T CELLS USE FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN LYON SUD HOSPITAL

EHA Library, Pierre Sesques, 293700

OUTPATIENT TREATMENT WITH LISOCABTAGENE MARALEUCEL (LISO-CEL) ACROSS A VARIETY OF CLINICAL SITES FROM THREE ONGOING CLINICAL STUDIES IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Carlos Bachier, 293701

DIFFUSE LARGE B CELL LYMPHOMA INVOLVING OSSEOUS SITES – RESPONSE ASSESSMENT BY PET/CT AND LONG-TERM OUTCOMES

EHA Library, Salma Ahsanuddin, 293702

TREATMENT STRATIFICATION IN B-CELL PTLD AFTER SOLID ORGAN TRANSPLANTATION BY TRANSPLANTED ORGAN, INTERNATIONAL PROGNOSTIC INDEX (IPI) AND RESPONSE TO RITUXIMAB: INTERIM RESULTS FROM THE PTLD-2 TRIAL

EHA Library, Heiner Zimmermann, 293703

RISK PROFILING OF FIRST-LINE DLBCL PATIENTS BY MEASURING CIRCULATING TUMOR DNA

EHA Library, Aparna Raval, 293704

COMBINATION TREATMENT WITH COPANLISIB, A PI3K INHIBITOR, AND GEMCITABINE IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS (RR-PTCL); A MULTICENTER, OPEN-LABEL, PHASE 1/2 TRIAL (COSMOS TRIAL)

EHA Library, Deok-Hwan Yang, 293705

HOW MUCH IS TOO MUCH FOR EARLY-STAGE EXTRANODAL NK/T-CELL LYMPHOMA: A MULTI-CENTRE RETROSPECTIVE STUDY COMPARING P-GEMOX REGIMEN VERSUS EPOCHL REGIMEN

EHA Library, Liang Wang, 293706

SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: DOSE-ESCALATION DATA FROM A PHASE 1/2 TRIAL

EHA Library, Martin Hutchings, 293707

CHARACTERISTICS AND OUTCOME OF BIOPSY-PROVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AFTER SOLID ORGAN TRANSPLANTATION: A REAL LIFE PICTURE ANNO 2020.

EHA Library, vibeke vergote, 293708

MONOTHERAPY (M-TX) ACTIVITY WITH THE FIRST CD20-TARGETED IMMUNOTOXIN, MT-3724, IN SUBJECTS (SBS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Roger Waltzman, 293709

DOSE-ADJUSTED EPOCH AND RITUXIMAB (DA-EPOCH-R) FOR THE TREATMENT OF DUAL EXPRESSOR AND DOUBLE HIT DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, MULTICENTER ITALIAN STUDY

EHA Library, Anna Dodero, 293710

A NOVEL SIX-GENE BASED PROGNOSTIC MODEL FOR PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Liang Wang, 293711

AUTOLOGOUS STEM CELL TRANSPLANTATION FOR UNTREATED TRANSFORMED INDOLENT B-CELL LYMPHOMA IN FIRST REMISSION: AN INTERNATIONAL, MULTI-CENTER PROPENSITY MATCHED STUDY

EHA Library, Collin Chin, 293712

PROGNOSTIC FACTORS (PF) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL) TREATED WITH RITUXIMAB-CHOP (RCHOP) ± RADIOTHERAPY (RT): IDENTIFICATION OF VERY LOW RISK SUBGROUPS

EHA Library, Theodoros Vassilakopoulos, 293713

PROGNOSTIC IMPACT OF 18F-FDG PET-CT IN PATIENTS WITH AGGRESSIVE B CELL LYMPHOMA TREATED WITH ANTI-CD19 CAR T CELLS

EHA Library, Pierre Sesques, 293714

EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH PRIMARY REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS OF THE SADAL STUDY

EHA Library, Josee. M Zijlstra, 293715

RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA IN SPAIN: A PRELIMINARY ANALYSIS OF THE GELTAMO-LDR2LSTUDY

EHA Library, Mariana Beatriz Bastos, 293716

HOW TO TREAT ELDERLY PATIENTS OVER 80 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA: ALL BENEFIT FROM RITUXIMAB AND SELECTED ONES FROM R-CHOP

EHA Library, Prokop Vodicka, 293717

RISK OF HEPATITIS B REACTIVATION AND CYTOMEGALOVIRUS RELATED INFECTIONS WITH MOGAMULIZUMAB: A RETROSPECTIVE STUDY OF INTERNATIONAL PHARMACOVIGILANCE DATABASE

EHA Library, Abhishek KUMAR, 293718

HIGH-DOSE METHOTREXATE (HDMTX) IN LYMPHOMA; IDENTIFYING METHOTREXATE LEVEL AT WHICH COMPLICATIONS ARE MORE LIKELY

EHA Library, Darragh O'Donoghue, 293719

REAL-WORLD DATA ON FRONTLINE INTENSIFICATION PROVIDING SURVIVAL BENEFITS IN PATIENTS WITH HIGHER-RISK PRIMARY CNS LYMPHOMA

EHA Library, Hao Yuan Wang, 293720

CLINICOPATHOLOGIC FEATURES & OUTCOMES OF DE NOVO TRANSFORMED INDOLENT LYMPHOMA.

EHA Library, Collin Chin, 293721

THE DIFFERENCE IN PREDICTIVE VALUE BETWEEN BONE MARROW INVOLVEMENT DETECTED USING FDG PET-CT AND BONE MARROW EXAMINATION IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Hanae Ida, 293722

CIRCULATING MICRORNAS IS A POTENTIAL PROGNOSTIC BIOMARKER IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Yan Ma, 293723